TW200413384A - 5-substituted 7,9-difluoro-5H-chromeno[3,4-f]quinoline compounds as selective progesterone receptor modulator compounds - Google Patents

5-substituted 7,9-difluoro-5H-chromeno[3,4-f]quinoline compounds as selective progesterone receptor modulator compounds Download PDF

Info

Publication number
TW200413384A
TW200413384A TW092121283A TW92121283A TW200413384A TW 200413384 A TW200413384 A TW 200413384A TW 092121283 A TW092121283 A TW 092121283A TW 92121283 A TW92121283 A TW 92121283A TW 200413384 A TW200413384 A TW 200413384A
Authority
TW
Taiwan
Prior art keywords
compound
difluoro
dihydro
trimethyl
group
Prior art date
Application number
TW092121283A
Other languages
English (en)
Chinese (zh)
Inventor
Lin Zhi
Cornelis Arjan Van Oeveren
Bijan Pedram
Donald Karanewsky
Original Assignee
Ligand Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharm Inc filed Critical Ligand Pharm Inc
Publication of TW200413384A publication Critical patent/TW200413384A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW092121283A 2002-10-11 2003-08-04 5-substituted 7,9-difluoro-5H-chromeno[3,4-f]quinoline compounds as selective progesterone receptor modulator compounds TW200413384A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41796802P 2002-10-11 2002-10-11

Publications (1)

Publication Number Publication Date
TW200413384A true TW200413384A (en) 2004-08-01

Family

ID=31994318

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092121283A TW200413384A (en) 2002-10-11 2003-08-04 5-substituted 7,9-difluoro-5H-chromeno[3,4-f]quinoline compounds as selective progesterone receptor modulator compounds

Country Status (12)

Country Link
US (1) US7163946B2 (enExample)
EP (1) EP1554283A1 (enExample)
JP (1) JP2006504737A (enExample)
AR (1) AR040781A1 (enExample)
AU (1) AU2003258051A1 (enExample)
CA (1) CA2501834A1 (enExample)
CL (1) CL2003001545A1 (enExample)
DE (1) DE20301728U1 (enExample)
HK (1) HK1055059A2 (enExample)
MX (1) MXPA05003801A (enExample)
TW (1) TW200413384A (enExample)
WO (1) WO2004033461A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US7026484B2 (en) 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
DE20301728U1 (de) 2002-10-11 2004-03-11 Ligand Pharmaceuticals, Inc., San Diego 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen
HK1055058A2 (en) 2002-10-11 2003-12-05 Ligand Pharmaceuticals Incorporated 5-CYCLOALKENYL 5H-CHROMENO[3,4-f]QUINOLINE DERIVATIVES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS
CA2501833A1 (en) * 2002-10-11 2004-04-22 Ligand Pharmaceuticals Incorporated 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5h-chromeno[3,4-f]quinolines as selective progesterone receptor modulator compounds
LT3820874T (lt) * 2018-07-12 2023-02-10 Eli Lilly And Company Selektyvūs estrogenų receptorių skaidytojai

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635941A (en) 1969-04-01 1972-01-18 Eastman Kodak Co Disperse mono azo dyes containing an acylamidotetrahydroquinoline group
US3907507A (en) 1971-04-26 1975-09-23 Heliodoro Monroy Rivera Novel apparatus for the obtention of substituted 1,2-dihydroquinolines
DK1130017T3 (da) 1990-11-30 2005-10-10 Otsuka Pharma Co Ltd Azolderivater og deres anvendelse som superoxidradikalinhibitorer
JPH04316557A (ja) 1991-04-16 1992-11-06 Kyorin Pharmaceut Co Ltd ６−アリール環状アントラニル酸誘導体
US5506102A (en) 1993-10-28 1996-04-09 Ligand Pharmaceuticals Incorporated Methods of using the A form of the progesterone receptor to screen for antagonists of steroid intracellar receptor-mediated transcription
US5693647A (en) 1994-12-22 1997-12-02 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
CZ176197A3 (cs) 1994-12-22 1998-09-16 Ligand Pharmaceuticals Incorporated Modulátory steroidových receptorů a způsoby jejich přípravy a použití
US6696459B1 (en) 1994-12-22 2004-02-24 Ligand Pharmaceuticals Inc. Steroid receptor modulator compounds and methods
RU2214412C2 (ru) 1996-06-27 2003-10-20 Лиганд Фармасетикалз Инкорпорейтед ПРОИЗВОДНЫЕ 8-ПИРИДОНО [5,6g] ХИНОЛИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБЫ С ИХ ИСПОЛЬЗОВАНИЕМ
US6380207B2 (en) 1998-02-13 2002-04-30 Abbott Laboratories Glucocortiocoid-selective antiinflammatory agents
BR9907788A (pt) * 1998-02-13 2001-10-30 Abbott Lab Agentes antiinflamatórios seletivos paraglicocorticóides
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
US6093826A (en) 1998-06-08 2000-07-25 Ligand Pharmaceuticals Incorporated Process for the preparation of C(5)-substituted 1,2-dihydro-5H-chromeno[3,4-f] quinolines
DE20301728U1 (de) 2002-10-11 2004-03-11 Ligand Pharmaceuticals, Inc., San Diego 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen
HK1055058A2 (en) 2002-10-11 2003-12-05 Ligand Pharmaceuticals Incorporated 5-CYCLOALKENYL 5H-CHROMENO[3,4-f]QUINOLINE DERIVATIVES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS
CA2501833A1 (en) 2002-10-11 2004-04-22 Ligand Pharmaceuticals Incorporated 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5h-chromeno[3,4-f]quinolines as selective progesterone receptor modulator compounds

Also Published As

Publication number Publication date
AU2003258051A1 (en) 2004-05-04
MXPA05003801A (es) 2005-06-08
US7163946B2 (en) 2007-01-16
CL2003001545A1 (es) 2005-01-07
JP2006504737A (ja) 2006-02-09
EP1554283A1 (en) 2005-07-20
DE20301728U1 (de) 2004-03-11
WO2004033461A1 (en) 2004-04-22
CA2501834A1 (en) 2004-04-22
HK1055059A2 (en) 2003-12-05
AR040781A1 (es) 2005-04-20
US20040152717A1 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
TWI615393B (zh) 丙烯酸類衍生物、其製備方法及其在醫藥上的用途
TW457234B (en) β-hydroxylactone derivatives of camptothecin, preparation processes, and anti-tumor pharmaceutical composition thereof
EP3312184A1 (en) Piperidine derivative and preparation method and pharmaceutical use thereof
WO2000066590A2 (en) Tetracyclic progesterone receptor modulator compounds and methods
CN109982701B (zh) SERD与CDK4/6抑制剂、PI3K/mTOR通路抑制剂的用途
TWI810185B (zh) 一種ｅｚｈ２抑制劑與ｂｔｋ抑制劑聯合在製備治療腫瘤的藥物中的用途
EP1718630A1 (en) DIBENZO CHROMENE DERIVATIVES AND THEIR USE AS ER&bgr; SELECTIVE LIGANDS
TW200808749A (en) Substituted bicyclic and tricyclic thrombin receptor antagonists
US6358947B1 (en) Tetracyclic progesterone receptor modulator compounds and methods
WO2021249463A1 (zh) 双环化合物及其应用
TW200413384A (en) 5-substituted 7,9-difluoro-5H-chromeno[3,4-f]quinoline compounds as selective progesterone receptor modulator compounds
JP2003518006A (ja) 環式カルバメートおよびアミド誘導体を含有する避妊組成物
US7071205B2 (en) 5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds
US7084151B2 (en) 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno[3,4-ƒ]quinolines as selective progesterone receptor modulator compounds
CN115611909A (zh) 四氢萘类化合物、其制备方法及其在医药上的应用
Kopsida et al. Novel bisnaphthalimidopropyl (BNIPs) derivatives as anticancer compounds targeting DNA in human breast cancer cells
TW201139441A (en) Substituted triazolo-pyrimidine compounds
TW202513542A (zh) 用於治療及/或預防腫瘤或細胞增生及纖維化疾病之吲哚啉衍生物
KR20060031956A (ko) ｐ90 리보솜 Ｓ6 키나제 1 (ＲＳＫ1)의 직접적인 키나제활성증진을 통한 간섬유화와 간경변증 예방 및 치료용약학조성물
BR112020008640B1 (pt) Composto derivado de dihidropiridina, composição farmacêutica, produto de combinação e uso do composto
JP2013505228A (ja) Ｓｍｏアンタゴニストとしてのピペリジン及びピペラジン誘導体